Background: Aortic stiffness is assessed by pulse wave velocity (PWV) and predicts the cardiovascular morbidity and mortality of hypertensive patients. To determine the long-term effects of intensive blood pressure (BP) lowering by antihypertensive drug therapy on aortic stiffness assessed by PWV, a single-blind randomized prospective study was performed. Methods: One hundred forty nondiabetic hypertensive patients (67.6 Ϯ 0.9 years old; systolic/diastolic BP: 177 Ϯ 1/101 Ϯ 1 mm Hg) were assigned to an intensive control group (IC) with a target BP of Ͻ130/85 mm Hg (n ϭ 71) or a moderate control group (MC) with a target BP of Ͻ140/90 mm Hg (n ϭ 69), and aortic stiffness was assessed every 3 months by measuring aortic PWV with a pulse pressure analyzer. Results: During the 12-month treatment period, BP significantly decreased to 129 Ϯ 1/78 Ϯ 1 mm Hg and 152
P
ulse wave velocity (PWV) is positively correlated with arterial wall stiffness, and larger arterial PWV values indicate greater stiffness. Aortic stiffness in hypertensive patients has been assessed noninvasively by measuring PWV along the aortoiliac pathway, and it predicts all-cause and cardiovascular mortality. [1] [2] [3] [4] A recent study demonstrated that aortic stiffness assessed by carotid-femoral PWV (cfPWV) is strongly associated with atherosclerosis of the aorta, the carotid artery, and peripheral arteries, 5 and thus monitoring PWV along the aortic pathway is a useful method of evaluating the degree of atherosclerosis and predicting all-cause and cardiovascular mortality.
The question of the degree to which blood pressure (BP) should be lowered to reduce cardiovascular morbidity and mortality among hypertensive patients has been a matter of debate. Because studies have shown that excessively vigorous BP reductions are associated with increased cardiovascular events, the relation between BP achieved and cardiovascular events was thought to be J-shaped. 6 -8 More recent studies, however, have demonstrated that intensive lowering of the BP of hypertensive patients is associated with a lower rate of cardiovascular events 9 and that control of BP within strict limits decreases the risk of macrovascular and microvascular complications in patients with type 2 diabetes independent of the class of antihypertensive drugs used to treat them. 10 -12 These studies suggest that intensive pressure reduction may have beneficial effects on arterial wall stiffness in hypertensive patients. Although a recent study demonstrated accelerated progression of aortic stiffness during a 6-year follow-up of 187 treated hypertensive patients in whom a BP of 150/87 mm Hg was achieved by antihypertensive therapy, 13 arterial wall stiffness might be prevented if BP were lowered more intensively.
The present study examined the long-term effects of intensive and moderate BP lowering on the arterial wall stiffness of hypertensive patients without diabetes mellitus. Arterial wall stiffness was evaluated by measuring PWV between the brachium and ankle (baPWV). Theoretically, acute BP reduction should retard transmission of the pulse wave along the arterial wall and reduce PWV, but whether sustained BP lowering for a longer term could produce a greater improvement in PWV had never been determined. In the present study, therefore, the ratios of the change in PWV (⌬PWV) to the change in BP after BP lowering for 3, 6, 9, and 12 months were evaluated and compared.
Methods

Study Population and Design
The single blind randomized prospective study consisted of 142 consecutive hypertensive patients who attended the outpatient hypertension clinic of Kawasaki Municipal Ida Hospital between October 2000 and March 2001 and for whom baseline arterial stiffness measurements by PWV were available. Patients with diabetes mellitus, arrhythmias, previous cardiovascular events, or peripheral arterial disease (ankle-brachial index [ABI] Ͻ0.9) were not included in the study. Hypertension was defined as a systolic BP of Ͼ140 mm Hg or a diastolic BP of Ͼ90 mm Hg as measured by sphygmomanometry. No patients with any form of secondary hypertension based on the results of classic laboratory and radiology tests were included. All hypertensive patients were randomly assigned to one of two groups, an intensive control (IC) group in which the target systolic/diastolic BP was Ͻ130/85 mm Hg (n ϭ 71), and a moderate control (MC) group in which the target systolic/diastolic BP was Ͻ140/90 mm Hg (n ϭ 71), and the assignment was performed by selecting a sealed envelope containing a paper written either "Ͻ130/85 mm Hg" or "Ͻ140/90 mm Hg." Two patients in the MC group were excluded from the study because of extremely high levels of serum creatinine (4.5 and 5.4 mg/dL). According to the indicated target BP, patients of both groups were treated with antihypertensive drugs, which consisted of calcium channel blockers (amlodipine, nicardipine, or nifedipine, in 110 patients), angiotensin-converting enzyme inhibitors (enalapril or imidapril, in 53 patients), angiotensin receptor blockers (candesartan or losartan, in 19 patients), ␣-blockers (doxazosin or prazosin, in 21 patients), ␤-blockers (atenolol or metoprolol, in 22 patients), and diuretics (furosemide or trichlormethiazide, in 9 patients), alone or in combination. The patients' physicians were unaware of their PWV levels during the 12-month treatment period. The study was approved by the review board of Kawasaki Municipal Ida Hospital, and informed consent was obtained from every subject.
Measurements
Every 3 months during the year after the start of treatment, PWV, ABI, heart rate (HR), and BP were determined with a pulse pressure analyzer (model: BP-203RPE, Nihon Colin, Tokyo, Japan) by the methods previously described. 14, 15 Briefly, pulse volume waveforms were recorded with plethymographic sensors placed on the right brachial artery and both posterior tibial arteries. Based on the phase velocity theory that the mean value of the phase velocity above 2 to 2.5 Hz is close to the wave front, 16 the wave front was automatically determined by using the components more than 5 Hz through a passfilter. Electrocardiograms were obtained with electrodes placed at two points on the left arm and one point on the right arm. The time between the wave front of the brachial waveform and the wave front of the posterior tibial waveform was measured as the time between the brachium and ankle (⌬Tba). The distance between the right brachial artery and posterior tibial artery was calculated according to the patient's height. The length of the path from the suprasternal notch to the brachium (Lb) was estimated from superficial measurements by using the following equation: Lb ϭ 0.2195 ϫ height of the patient (in centimeters) Ϫ 2.0734. The length of the path from the suprasternal notch to the ankle (La) was estimated from superficial measurements by using the following equation: La ϭ 0.8129 ϫ height of the patient (in centimeters) ϩ 12.328. Finally, baPWV was calculated by using the following equation: (La Ϫ Lb)/ ⌬Tba. The baPWV values measured by this method are significantly correlated with cfPWV 17 and aortic PWV measured by the catheter method, 15 with high correlation coefficients of 0.81 and 0.87, respectively, although baPWV is generally higher than cfPWV or invasively measured PWV. Based on a mathematical model, MoensKorteweg equation, 18 PWV is inversely proportional to the square root of the vessel's diameter. In addition, the dominant component of peripheral arteries is collagen and smooth muscle cells, whereas that of the proximal aorta is elastin. Because the elastic modulus of collagen is much higher than that of elastin, greater distance from the heart makes the arteries stiffer. Because the arterial pathway between the brachium and ankle includes a long segment of peripheral smaller artery, the baPWV indicates higher values than the PWV measured at the aortic segment. The best 10 consecutive pulses were analyzed, and the average baPWV was recorded as the PWV in the present study. The baPWV was measured when the patients' HR was stable at 60 to 80 beats/min after at least a 5-min rest. Two measurements were performed in each leg, and the average values were used in the analysis. Values are expressed in units of centimeters per second. When the baPWV was measured in our institution, the inter-and intraobserver discrepancies ranged from Ϫ64 to 32 cm/sec (mean Ϯ SD, Ϫ6 Ϯ 27 cm/sec) and from Ϫ75 to 78 cm/s (mean Ϯ SD, Ϫ9 Ϯ 40 cm/s), respectively, and the coefficient of variation was 4.7% and 4.2%, respectively. Pearson's corre-lation coefficient was 0.99 for interobserver repeatability (P Ͻ .0001) and 0.97 for intraobserver repeatability (P Ͻ .0001).
For measurements of total cholesterol (TC), triglyceride (TG), HDL, LDL, creatinine, and C-reactive protein (CRP) concentrations, venous blood samples were drawn in the morning after an overnight fast on the same days as the PWV measurements were taken.
Statistical Analyses
Fisher's exact test was used for gender and frequency of patients' characteristics, except age and body mass index, which were analyzed by the Mann-Whitney U test. Differences in numbers of patients taking individual antihypertensive drugs and their daily doses were tested by Fisher's exact test and Student t test, respectively. The changes in biological parameters and differences in them between the groups were analyzed by two-way analysis of variance for repeated measures combined with the Newman-Keuls post hoc test. The relationships between each parameter and PWV were assessed by Pearson correlation coefficients for continuous variables and Student t test for categorical variables. A value of P Ͻ .05 was considered significant. Data are presented as means Ϯ SEM. The number of patients in the present study was sufficient for the estimated required sample size (47.15 in each group) with an ␣-error of 0.05 and a power of 0.8. Table 1 shows that age, gender distribution, height, body mass index, smoker ratio, pack years, and rates of complication by hyperlipidemia at the start of the treatment period were similar in the IC group and MC group. Use of the antihypertensive drugs and the combinations of the antihypertensive drugs were similar in both groups. At the start of the treatment period, the following average values were obtained in the IC group and MC group: ABI, 1.12 Ϯ 0.02 and 1.11 Ϯ 0.01, respectively; serum creatinine, 0.94 Ϯ 0.11 mg/dL (0.50 -2.90) and 0.91 Ϯ 0.05 mg/dL (0.40 -2.90), respectively; serum TC, 214 Ϯ 6 mg/dL and 211 Ϯ 5 mg/dL, respectively; serum TG, 172 Ϯ 16 mg/dL and 169 Ϯ 13 mg/dL, respectively; serum HDL, 58 Ϯ 3 mg/dL and 63 Ϯ 2 mg/dL, respectively; serum LDL, 129 Ϯ 7 mg/dL and 122 Ϯ 7 mg/dL, respectively; and serum CRP, 0.14 Ϯ 0.02 mg/dL and 0.19 Ϯ 0.03 mg/dL, respectively. There were no significant differences in these clinical or biological parameters between the two groups, and no significant changes in them were observed in either group during the 12-month treatment period.
Results
Patient Characteristics
Cross-Sectional Observation at the Start of the Treatment Period
At the start of the treatment period, the systolic/diastolic BP, mean arterial pressure (MAP), pulse pressure (PP), HR, and PWV values of all of the hypertensive patients averaged 177 Ϯ 1/101 Ϯ 1 mm Hg, 127 Ϯ 1 mm Hg, 76 Ϯ 1 mm Hg, 71 Ϯ 1 beats/min, and 1831 Ϯ 32 cm/sec, respectively. Baseline PWV was not correlated with any clinical or biological parameters except age (y ϭ 725 ϩ 16x, Rϭ 0.445, P Ͻ .0001) and PP (y ϭ 59.9 ϩ 0.01x, R ϭ 0.239, P ϭ .0001). Fig. 1 shows the BP and PWV of the IC group and MC group during the 12-month treatment period. At the start of the treatment period, the systolic/diastolic BP values were similar, averaging 176 Ϯ 2/101 Ϯ 1 mm Hg and 178 Ϯ 2/101 Ϯ 1 mm Hg, respectively. After 3 months, they had decreased significantly to 135 Ϯ 1/81 Ϯ 1 mm Hg and 148 Ϯ 2/85 Ϯ 1 mm Hg, respectively, and the decreases were maintained until the end of the treatment period. After the start of antihypertensive drug therapy, the systolic/diastolic BP values of the IC group were always lower than those of the MC group. At the start of the treatment period, the PWV values were similar in both groups and averaged 1779 Ϯ 41 cm/sec and 1885 Ϯ 50 cm/sec, respectively. In the IC group, PWV significantly decreased to 1634 Ϯ 33 cm/sec by 6 months, and the decrease was maintained until the end of the treatment period. However, the PWV of the MC group was unchanged during the antihypertensive drug therapy. The HR values of the IC group and MC group were similar at the start of the treatment period, averaging 72 Ϯ 1 beats/min and 71 Ϯ 1 beats/min, respectively, and unchanged during the 12-month treatment period. In addition, to assess the changes in PWV independently of BP changes, we evaluated the ratios of the ⌬PWV to the change in MAP (⌬MAP) during the 12- month period and their determinants, as other investigators reported previously. 13 We chose MAP rather than systolic/ diastolic BP and PP, because MAP is not directly dependent on arterial stiffness. Fig. 2 shows a rightward-shifted scattergram of ⌬MAP and ⌬PWV in the MC group with a greater variance compared to that in the IC group. In addition, the ⌬PWV/⌬MAP ratio was similar in the IC group and the MC group, averaging 5.9 Ϯ 0.9 and 5.7 Ϯ 3.8, respectively. The ⌬PWV/⌬MAP ratio was significantly correlated with baseline PWV values (y ϭ 1820 ϩ 2.14x, R ϭ 0.267, P ϭ .0014), serum creatinine levels (y ϭ 0.951 ϩ 0.003x, R ϭ 0.197, P ϭ .02), and serum TG levels (y ϭ 168 Ϫ 0.62x, R ϭ 0.295, P ϭ .001), but was not associated with the other clinical or biological parameters. Table 2 shows ⌬MAP, ⌬PWV, and the ⌬PWV/⌬MAP ratio after BP lowering for 3, 6, 9, and 12 months in the patients of the IC group. Although there was no significant difference in ⌬MAP after treatment for 3, 6, 9, and 12 months, ⌬PWV and the ⌬PWV/⌬MAP ratio were significantly greater after BP lowering for 12 months than after BP lowering for 3 months. Table 3 shows how many patients were prescribed individual drugs and how many doses of the drug were prescribed to the IC group and MC group. Although the numbers of patients treated each antihypertensive drug were similar in both groups, the daily dose of amlodipine was significantly higher in the IC group than in the MC group. The daily doses of the other drugs were similar in both groups. Therefore, analyses were also performed in the patients treated with antihypertensive drugs including amlodipine. In the patients receiving amlodipine, as shown in the left panel of Fig. 3 , the systolic/diastolic BP of the IC group significantly decreased from 177 Ϯ 3/101 Ϯ 1 mm Hg to 120 Ϯ 2/77 Ϯ 1 mm Hg during the 12-month treatment period, and the systolic/diastolic BP of the MC group significantly decreased from 180 Ϯ 3/102 Ϯ 2 mm Hg to 158 Ϯ 2/90 Ϯ 2 mm Hg during the 12-month treatment period. The systolic/diastolic BP values of the IC group were always lower than those of the MC group. The PWV of the IC group significantly decreased from 1792 Ϯ 38 cm/sec to 1575 Ϯ 33 cm/sec during the 12-month treatment period, whereas the PWV of the MC group was unchanged during the 12-month treatment period. In addition, analyses were carried out in the patients who did not receive amlodipine. As shown in the right panel of Fig. 3 , during the 12-month treatment period, the systolic/diastolic BP similarly decreased in both the IC group (from 176 Ϯ 2/101 Ϯ 1 mm Hg to 139 Ϯ 2/79 Ϯ 1 mm Hg) and the MC group (from 175 Ϯ 3/101 Ϯ 2 mm Hg to 144 Ϯ 3/83 Ϯ 2 mm Hg). In either group, the target systolic BP was not achieved without amlodipine. At the start of the treatment period, the PWV values of the IC group and the MC group averaged 1768 Ϯ 82 cm/sec and 1957 Ϯ 73 cm/sec, respectively. In both groups, PWV was unchanged during the antihypertensive drug therapy not including amlodipine.
Longitudinal Observation of BP and PWV
Duration-Dependent Effects of BP Lowering on PWV
Assessment of Individual Antihypertensive Drugs
Discussion
The present study showed that moderate BP lowering failed to decrease the PWV of hypertensive patients. Intensive BP lowering, however, significantly reduced the PWV of the hypertensive patients. Moreover, the sustained BP lowering for 12 months in the IC group significantly enhanced the PWV reduction in response to the BP reduction compared to the BP lowering for 3 months, despite the fact that 3-and 12-month treatment decreased BP similarly. Although PWV reflects functional and anatomic arterial wall elasticity, the results of the present study suggest that anatomic elasticity can be improved if intensive BP lowering to near normal levels has been sustained for at least 12 months. This is consistent with previous studies demonstrating that PWV predicts the cardiovascular mortality and morbidity of hypertensive patients. [1] [2] [3] [4] The PWV can, therefore, be used as an index of the success of BP control during long-term antihypertensive treatment.
In the MC group, PWV did not significantly change during the 12-month treatment period despite a significant decrease in the BP. Although acute BP reduction is known to retard transmission of the pulse wave along the arterial wall and reduce PWV, some compensatory mechanisms, such as the sympathetic nervous system and renal mechanisms, may be activated during sustained BP lowering and inhibit the decrease in PWV. Therefore, intensive BP lowering can overwhelm the compensatory mechanisms and elicit a significant decrease in PWV.
Age, 13, 17, 19, 20 21 may impact PWV values and their progression in both hypertensive patients and normotensive subjects. The results of the present study were in part consistent with those of previous studies and demonstrated significant correlations between baseline PWV and both age and PP, and significant correlations between ⌬PWV/⌬MAP ratios and baseline PWV, serum creatinine levels, and serum TG levels. However, all of these clinical and biological parameters and the changes in them, except the BP parameters, were similar in the IC group and the MC group, suggesting that BP control during the treatment period is an important determinant of whether the PWV of hypertensive patients decreases or not.
Although PWV significantly decreased during the 12-month treatment period in the IC group compared to the MC group, the ⌬PWV/⌬MAP ratios in the two groups were similar. These results suggest that a sustained decrease in the PWV of hypertensive patients depends on long-term reduction of BP and that the relationship between PWV and BP is linear between 129/78 mm Hg and 152/87 mm Hg, which were the BP values achieved in the IC group and the MC group, respectively.
Amlodipine is a long-acting dihydropyridine calcium channel blocker and has a significant effect in slowing the progression of carotid artery atherosclerosis. 26 The daily dose of amlodipine in the present study was significantly higher in the IC group than in the MC group. The IC group receiving higher doses of amlodipine achieved the target systolic BP, and their PWV significantly decreased, whereas the target BP or significant decrease in PWV was not achieved in the MC group receiving lower doses of amlodipine or in either group that did not receive amlodipine. These results suggest that higher doses of amlodipine are useful for achieving intensive BP control and reducing PWV. Because amlodipine has been reported to better maintain its BP-lowering effects than the dihydropyridine calcium channel blocker nifedipine, 27 the higher doses of amlodipine may have contributed to the maintenance of better antihypertensive efficacy in the IC group. The shorter antihypertensive efficacy at lower doses of amlodipine may lead to BP fluctuations and create excessive tension in the arterial wall, possibly through activation of the sympathetic nervous system. This may explain why the PWVs of the MC group receiving lower doses of amlodipine and the IC group not receiving amlodipine failed to decrease despite a significant decrease in BP.
In conclusion, the results of the present study demonstrated that long-term intensive BP control significantly decreased PWV, which reflects anatomic arterial wall elasticity and has been reported to predict the cardiovascular mortality and morbidity of hypertensive patients. Therefore, PWV can be used as an index of BP control aimed at preventing cardiovascular complications.
